需要对EMT和乳腺癌转移进行PBRM1-依赖的PBAF准
bioRxiv : the preprint server for biology
|November 24, 2025
概括
PBAF染色体改造器,特别是其PBRM1子单元,对于乳腺癌转移和上皮-介质细胞转变至关重要. PBRM1向特定的基因促进体,影响细胞迁移和存活,并且可能代表晚期癌症的治疗标.
科学领域:
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
背景情况:
- 包括PBAF在内的SWI/SNF染色体重塑剂通过调动核细胞组来调节基因表达.
- PBAF亚单元突变与发育和疾病表型有关,但它们的生物化学功能尚不清楚.
- 与PBAF突变相关的体内表型并不总是在基于细胞的系统中复制.
研究的目的:
- 调查PBAF亚单元PBRM1在TGFB1介导的上皮层-介质细胞转变 (EMT) 和乳腺癌转移中的作用.
- 阐明PBRM1在EMT期间影响基因表达的机制.
- 探索PBAF在癌症发病和进展中的双重作用.
主要方法:
- 在EMT期间,乳腺细胞的表观基因分析.
- 在体外和体内研究PBRM1在EMT和转移中的作用.
- 分析PBRM1对诱导性促进体的向及其对DNA可访问性的影响.
主要成果:
- 在乳腺细胞和小鼠乳腺癌转移中,PBRM1对于TGFB1诱导的EMT至关重要.
- PBRM1将PBAF引导到由H3K14ac标记的诱导性促进体,并促进TGFβ1诱导性转录因子的DNA可访问性.
- 删除PBRM1影响了构成性和诱导性基因表达,解释了依赖上下文的表型.
结论:
- PBRM1是EMT和乳腺癌转移的关键调节者,通过调节特定基因位置的染色质可访问性来起作用.
- 在EMT期间PBAF在基因调节中的作用为PBRM1缺乏细胞中观察到的上下文依赖表型提供了洞察力.
- 在晚期转移性癌症中,PBAF可能成为脆弱性,尽管PBRM1删除可能促进早期癌症发病.
相关概念视频
Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


